Please provide your email address to receive an email when new articles are posted on . “We believe that these results are quite powerful and informative,” Christopher Seder, MD, thoracic surgeon at ...

LOS ANGELES -- Surgeries to remove small tumors in stage IA non-small cell lung cancer (NSCLC) were associated with varying odds of long-term survival depending on the amount of lung removed, based on ...

For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC) has been surgical resection, typically minimally invasive lobectomy with systematic lymph ...

Assessment of survival benefit with immunotherapy in combination with adjuvant chemoradiation in pathologic stage II-IIIB non-small cell lung cancer. Adjuvant icotinib of 12 months versus observation ...

Non-small cell lung cancer (NSCLC) remains the most prevalent type of lung cancer and a leading cause of cancer-related mortality worldwide. Surgical ...

PTNB before surgery in stage 1 NSCLC patients is linked to higher local-regional recurrence and mortality rates. The study included 2026 patients, with 38.6% undergoing PTNB, showing higher recurrence ...

Sample management algorithm for average-risk patients. A. Resection suggested over stereotactic body radiotherapy or ablative techniques. B. Resection by a board-certified thoracic surgeon suggested.

Response was assessed after completion of induction chemotherapy, with chest and upper abdominal CT scan. Brain, chest, and abdominal CT scans were repeated at completion of chemoradiation therapy, ...